Author: Sarkar, Chandan; Mondal, Milon; Torequl Islam, Muhammad; Martorell, Miquel; Docea, Anca Oana; Maroyi, Alfred; Sharifi-Rad, Javad; Calina, Daniela
Title: Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives Cord-id: nh5vzsiq Document date: 2020_9_15
ID: nh5vzsiq
Snippet: The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited availability. Several old antivirals, antimalarial, and biological drugs are being reconsidered as possible therapies. The effectiveness of the controversial treatment options for COVID-19 such as non
Document: The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited availability. Several old antivirals, antimalarial, and biological drugs are being reconsidered as possible therapies. The effectiveness of the controversial treatment options for COVID-19 such as nonsteroidal antiinflammatory drugs, angiotensin 2 conversion enzyme inhibitors and selective angiotensin receptor blockers was also discussed. A systemic search in the PubMed, Science Direct, LitCovid, Chinese Clinical Trial Registry, and ClinicalTrials.gov data bases was conducted using the keywords “coronavirus drug therapy,†passive immunotherapy for COVID-19’, “convalescent plasma therapy,†(CPT) “drugs for COVID-19 treatment,†“SARS-CoV-2,†“COVID-19,†“2019-nCoV,†“coronavirus immunology,†“microbiology,†“virology,†and individual drug names. Systematic reviews, case presentations and very recent clinical guidelines were included. This narrative review summarizes the available information on possible therapies for COVID-19, providing recent data to health professionals.
Search related documents:
Co phrase search for related documents- action mechanism and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- action mechanism and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- action mechanism and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- action mechanism and acute respiratory distress ards: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- action mechanism and adaptive design: 1
- action mechanism and adaptive immune system: 1
- action mechanism and adaptive phase: 1, 2
- action mechanism and adenosine analog: 1, 2
- action mechanism and long history: 1, 2, 3, 4, 5
- action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and lung activation: 1, 2, 3
- action mechanism and lung cancer: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- action mechanism and lung damage: 1, 2, 3, 4, 5, 6
- action mechanism and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
- action mechanism and lung phase: 1
- action mechanism and lung viral infection: 1, 2, 3, 4
- action mechanism and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- action mechanism and lymph node: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date